{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360011143738569216.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1093/jac/dkl385"}},{"identifier":{"@type":"URI","@value":"http://academic.oup.com/jac/article-pdf/58/5/1031/2230701/dkl385.pdf"}}],"dc:title":[{"@value":"Sequential treatment with lamivudine and interferon-  monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380011143738569217","@type":"Researcher","foaf:name":[{"@value":"M. Shi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011143738569216","@type":"Researcher","foaf:name":[{"@value":"R. S. Wang"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011143738569221","@type":"Researcher","foaf:name":[{"@value":"H. Zhang"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011143738569218","@type":"Researcher","foaf:name":[{"@value":"Y. F. Zhu"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011143738569090","@type":"Researcher","foaf:name":[{"@value":"B. Han"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011143738569219","@type":"Researcher","foaf:name":[{"@value":"Y. Zhang"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011143738569220","@type":"Researcher","foaf:name":[{"@value":"L. J. Jin"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011143738569088","@type":"Researcher","foaf:name":[{"@value":"Z.-J. Yang"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011143738569089","@type":"Researcher","foaf:name":[{"@value":"Y. P. Xu"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03057453"},{"@type":"EISSN","@value":"14602091"}],"prism:publicationName":[{"@value":"Journal of Antimicrobial Chemotherapy"}],"dc:publisher":[{"@value":"Oxford University Press (OUP)"}],"prism:publicationDate":"2006-09-06","prism:volume":"58","prism:number":"5","prism:startingPage":"1031","prism:endingPage":"1035"},"reviewed":"false","url":[{"@id":"http://academic.oup.com/jac/article-pdf/58/5/1031/2230701/dkl385.pdf"}],"createdAt":"2006-09-20","modifiedAt":"2017-08-22","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050022476722646656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B"},{"@language":"ja-Kana","@value":"ニホンジン マンセイ Bガタ カンエン カンジャ ニオケル エンテカビル カラ ペグインターフェロンα エノ ソウキ キリカエ オ トモナウ チクジ リョウホウ"},{"@language":"ja","@value":"日本人慢性B型肝炎患者における、エンテカビルからペグインターフェロンαへの早期切り替えを伴う逐次療法"},{"@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon‐α in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693139692416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Factors associated with the effect of interferon‐α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706236945920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709456608384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617824940288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181214789888","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567189633761024","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: A pilot study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656190200320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1093/jac/dkl385"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_P0mbdyouKAtI4BKcXczxgaKOr67"},{"@type":"CROSSREF","@value":"10.3851/imp3240_references_DOI_P0mbdyouKAtI4BKcXczxgaKOr67"},{"@type":"CROSSREF","@value":"10.1111/hepr.12488_references_DOI_P0mbdyouKAtI4BKcXczxgaKOr67"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0742-5_references_DOI_P0mbdyouKAtI4BKcXczxgaKOr67"},{"@type":"CROSSREF","@value":"10.1089/jir.2014.0234_references_DOI_P0mbdyouKAtI4BKcXczxgaKOr67"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_P0mbdyouKAtI4BKcXczxgaKOr67"},{"@type":"CROSSREF","@value":"10.1007/s00535-020-01707-6_references_DOI_P0mbdyouKAtI4BKcXczxgaKOr67"},{"@type":"CROSSREF","@value":"10.1111/hepr.13050_references_DOI_P0mbdyouKAtI4BKcXczxgaKOr67"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_P0mbdyouKAtI4BKcXczxgaKOr67"},{"@type":"CROSSREF","@value":"10.1007/s00535-017-1360-z_references_DOI_P0mbdyouKAtI4BKcXczxgaKOr67"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0645-5_references_DOI_P0mbdyouKAtI4BKcXczxgaKOr67"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_P0mbdyouKAtI4BKcXczxgaKOr67"}]}